TERT and cancer: Specifically, human TERT promoter drives GAL4 expression in a cancer-specific manner, and GAL4 subsequently binds to UAS to activate a promoter driving Cas9 nuclease expression, ultimately promoting preferential Cas9 expression in cancer cells through a genetic cascade.